Johnson & Johnson (JNJ)
| Market Cap | 454.31B |
| Revenue (ttm) | 90.63B |
| Net Income (ttm) | 22.66B |
| Shares Out | 2.41B |
| EPS (ttm) | 9.33 |
| PE Ratio | 20.21 |
| Forward PE | 17.30 |
| Dividend | $5.20 (2.76%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 9,022,927 |
| Open | 187.06 |
| Previous Close | 185.98 |
| Day's Range | 186.91 - 189.78 |
| 52-Week Range | 140.68 - 189.78 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 186.13 (-1.33%) |
| Earnings Date | Oct 14, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $186.13, which is a decrease of -1.33% from the latest price.
News
October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net...
Examining JNJ Breakout: Bull Flag & Options Show Upside Potential
Johnson & Johnson (JNJ) has shined in the healthcare space, rallying 5% this week and 30% in 2025. An upgrade from Wells Fargo added momentum to the stock rally on Friday.
Why JNJ Stock Defines Shareholder Supremacy In Healthcare
Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder ...
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six...
Best Dividend Aristocrats For October 2025
Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristoc...
'I'm an optimist,' says Johnson & Johnson CEO on its R&D investment
CNBC's Jim Cramer sits down with Johnson & Johnson CEO Joaquin Duato to talk about the company's outlook, President Trump's 100% tariff on some pharmaceutical imports, cancer treatment innovation and ...
Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato
CNBC's Jim Cramer sits down with Johnson & Johnson CEO Joaquin Duato to talk about the company's outlook, President Trump's 100% tariff on some pharmaceutical imports, cancer treatment innovation and ...
Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDT Company Participants Tom Cavanaugh - Company Group Chairman for North America Innovative ...
J&J to withdraw acid reflux device from non-US markets, Bloomberg News reports
Johnson & Johnson will withdraw a device to treat acid reflux disease from markets outside the U.S., Bloomberg News reported on Tuesday, citing a company letter sent to doctors.
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of c...
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study TORONTO , Sept. 19, 2025 /PRNewswi...
Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
Pending the European Commission's final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibo...
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sus...
Josh Brown's Best Stocks in the Market: Johnson & Johnson
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's adding Johnson & Johnson to his "best stocks in the market"
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
21 abstracts from across the Company's portfolio highlight clinical and real-world data on major depressive disorder, treatment-resistant depression and schizophrenia New Phase 3 data demonstrate the ...
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
J&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in Waterloo
WATERLOO, ON / ACCESS Newswire / September 12, 2025 / J&J Painting, a trusted name in residential and commercial painting services, has been recognized with the 2026 Consumer Choice Award in the Paint...
This year healthcare is the worst performing part of the market by far, says Jim Cramer
'Mad Money' host Jim Cramer revisits Johnson & Johnson's stock after a rough year for healthcare.
After a couple years in purgatory, Johnson & Johnson is now having a strong year, says Jim Cramer
'Mad Money' host Jim Cramer revisits Johnson & Johnson's stock after a rough year for healthcare.
Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. 1
Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Joaquin Duato - CEO & Chairman John Reed - Executive Vice Pre...
Trump's Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.
The effort falls well short of banning the ads outright, but could dent sales.
US FDA approves J&J's bladder cancer treatment
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative ...